MAGE-A9-derived peptide–HLA-A*02:01–T cell receptor complex (MAGE-A9–HLA-A2–TCR complex)

The MAGE-A9-derived HLA-A2 peptide–T cell receptor complex is a tripartite molecular assembly consisting of a specific peptide fragment from the Melanoma-associated antigen A9 (MAGE-A9), the Human Leukocyte Antigen A*02:01 (HLA-A2) molecule, and a cognate T cell receptor (TCR). MAGE-A9 is a member of the cancer-testis antigen family, which is typically expressed only in the testis and placenta but is aberrantly upregulated in various malignancies, including bladder, lung, and liver cancers (Source 2.3.4, 2.3.5). This restricted expression pattern makes the MAGE-A9 pMHC complex an attractive target for adoptive T cell therapies, such as TCR-engineered T cells (TCR-T) and bispecific T cell engagers (Source 2.5.1). These therapies aim to redirect the patient's immune system to recognize and eliminate MAGE-A9-positive tumor cells in an HLA-restricted manner, often targeting the specific peptide sequence ALSVMGVYV (Source 3.2.2). However, the high sequence homology among MAGE family members poses a significant challenge for drug development, as cross-reactivity can lead to severe off-target toxicities (Source 3.2.4). Current research focuses on identifying high-affinity TCRs that can selectively bind this complex without affecting healthy tissues or other MAGE proteins (Source 3.2.3, 3.2.5).

Other names

Melanoma-associated antigen A9-derived peptide–HLA-A*02:01–T cell receptor complexMAGE-A9/HLA-A2/TCR complexMAGE-A9 pMHC-TCR complexMAGE-A9-derived HLA-A2 peptide–T cell receptor complex

TCR-mediated redirection of T cells to recognize and kill MAGE-A9-expressing tumor cells in an HLA-A*02:01-restricted manner.